OncoImmunology (Jan 2020)

Firing up the cold tumors by targeting Vps34

  • Bassam Janji,
  • Meriem Hasmim,
  • Santiago Parpal,
  • Guy Berchem,
  • Muhammad Zaeem Noman

DOI
https://doi.org/10.1080/2162402X.2020.1809936
Journal volume & issue
Vol. 9, no. 1

Abstract

Read online

Cancer immunotherapy based on anti-PD-1/PD-L1 blockade is particularly effective in responding to patients with hot tumors. These tumors are characterized by the accumulation of proinflammatory cytokines and T cell infiltration. In our recent report published in Science Advances, we demonstrate that targeting the autophagy-related protein Vps34 switched cold immune desert tumors into hot inflamed immune-infiltrated tumors and enhanced the efficacy of anti-PD-1/PD-L1. Our study provides the preclinical rationale to set up combination immunotherapy clinical trials using selective Vps34 inhibitors and immune checkpoint blockers in melanoma and CRC.

Keywords